Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
boston top stories
detroit blog main
detroit top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
4
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
drugs
fda
national
biotech
cancer
clinical trials
eli lilly
indiana blog main
indiana top stories
jefferies
roche
accelerator
advaxis
age related macular degeneration
agios pharmaceuticals
aimmune therapeutics
airbnb
What
big
4
×
companies
meeting
week
admits
ago
american
approval
arguments
ash
bio
biotechs
blood
bosley's
bosley’s
bridge
bucks
cas
ceo
class
classes
combinator
commercialized
competitors
country
crime
crispr
decades
departure
diego
disease
drug
drugs
dug
editas
exit
fda
gathering
guiding
hematology’s
Language
unset
Current search:
photo
×
" raleigh-durham top stories "
×
big
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
